References
  1. Jones LC, Kaste SC, Karol SE, et al. Team approach: Management of osteonecrosis in children with acute lymphoblastic leukemia [published online ahead of print, 2020 Aug 29]. Pediatr Blood Cancer. 2020;e28509. doi:10.1002/pbc.28509
  2. Mattano LA Jr, Devidas M, Nachman JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906‐915. doi:10.1016/S1470-2045(12)70274-7
  3. Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M. Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(4):e208‐e211. doi:10.1016/j.oooo.2018.05.008
  4. Yassin MA, Moustafa AH, Nashwan AJ, et al. Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia. Clin Med Insights Blood Disord. 2015;8:19‐23. Published 2015 Jul 23. doi:10.4137/CMBD.S24628